SigmundH.HsuMD

Neurology • Houston, TX

Neurooncology

Assistant Professor, Neurosurgery, University of Texas Medical School, Houston

Join to view full profile

Dr. Hsu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hsu's full profile

Already have an account?

Office
6400 Fannin St
Suite 2800
Houston, TX 77030
Phone+1 713-486-8000

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 1999 - 2001
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1996 - 1999
Yale-New Haven Medical CenterInternship, Internal Medicine, 1995 - 1996
The Warren Alpert Medical School of Brown UniversityClass of 1995

Certifications & Licensure

TX State Medical License 2002 - 2026
American Board of Psychiatry and Neurology Neurology

Clinical Trials

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Start of enrollment: 2013 Aug 01
Suspended
Phase 1, Phase 2
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma Start of enrollment: 2021 Oct 11
Completed
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.
Yang Yu, Austin Arrigo, Ankush Chandra, Chuling Zhuang, Mariana K Najjar
Biorxiv. 2025-02-26
The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.
Kamand Khalaj, Michael A Jacobs, Jay-Jiguang Zhu, Yoshua Esquenazi, Sigmund Hsu
Cancers. 2024-07-02
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Samuel A Goldlust, Louis B Nabors, Sigmund Hsu, Nimish Mohile, Paul J Duic
Neuro-Oncology Advances. 2024-01-18

Journal Articles

MRI-Guided Radiotherapy for Head and Neck Cancer: Initial Clinical Experience
M Cao, S Hsu, Y Yang, M L Steinberg, A M Chen, J Lamb, Clinical & translational oncology

Press Mentions

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate CommencesOctober 23rd, 2020